Renal Cell Carcinoma – Landscape & Forecast – Disease Landscape & Forecast

The renal cell carcinoma market is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. Combination regimens, including Opdivo plus Yervoy (Bristol Myers Squibb / Ono Pharmaceutical) and Keytruda (Merck & Co.) plus Inlyta (Pfizer), are revolutionizing the treatment of advanced disease. The approval and uptake of Opdivo plus Cabometyx (Exelixis / Ipsen) and Keytruda plus Lenvima / Kisplyx (Eisai) will also drive fierce competition in this setting. Treatment choices for early-stage disease are also increasing with Keytruda’s label expansion as an adjuvant therapy. Moreover, the FDA’s approval of Welireg (Merck & Co.) will reshape the treatment of VHL-associated tumors. The anticipated entry of other agents such as savolitinib (AstraZeneca) will further diversify treatment options during the forecast period and create a highly competitive and dynamic market.

Questions answered

  • What is the size of the early-stage and advanced / metastatic drug-treatable renal cell carcinoma population, and how will drug-treatment rates change over time?
  • What is the expected market impact of recent drug approvals and label expansions of novel combinations incorporating Opdivo, Cabometyx, Welireg, Lenvima / Kisplyx, and Keytruda for renal cell carcinoma?
  • Which are the most promising emerging therapies in the late-phase pipeline, and how will they shape the future of the renal cell carcinoma market?
  • What are the drivers and constraints in renal cell carcinoma, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Solution Enhancement

Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Renal Cell Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
    • Key findings
      • Key updates
        • Q4 2022
          • November 2022
        • Q3 2022
          • September 2022
          • August 2022
          • July 2022
        • Q2 2022
          • April 2022
        • Q1 2022
          • March 2022
          • February 2022
          • January 2022
        • Q4 2021
          • December 2021
      • Market outlook
        • Key findings
          • Market share of drug classes for renal cell carcinoma: 2021
          • Market share of drug classes for renal cell carcinoma: 2031
          • Drug-treatable population share and major-market sales share in renal cell carcinoma: 2021
          • Drug-treatable population share and major-market sales share in renal cell carcinoma: 2031
          • Population positioning of current therapies in renal cell carcinoma
          • Population positioning of emerging therapies in renal cell carcinoma
          • Renal cell carcinoma SWOT analysis
        • Market drivers and constraints
          • What factors are driving the market for renal cell carcinoma?
          • What factors are constraining the market for renal cell carcinoma?
          • Major-market sales for renal cell carcinoma by drug-treatable population: 2021-2031
          • Major-market sales of immune oncology therapies for renal cell carcinoma: 2021-2031
          • Major-market sales of angiogenesis inhibitors for renal cell carcinoma: 2021-2031
        • Segment-specific trends
          • Patient-share dynamics of therapies for early-stage (stage I-III) renal cell carcinoma, United States: 2021-2031
          • Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
          • Patient-share dynamics of key therapies in first-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
          • Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
          • Patient-share dynamics of key therapies in second-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
          • Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, United States: 2021-2031
          • Patient-share dynamics of key therapies in third-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
          • Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, United States, 2021-2031
          • Patient-share dynamics of key therapies in fourth-line advanced or metastatic renal cell carcinoma, Japan: 2021-2031
      • Forecast
        • Market forecast assumptions
        • Market forecast dashboard
      • Etiology and pathophysiology
        • Disease overview
          • Progression of renal cell carcinoma
          • Anatomy and histology of renal cell carcinoma
          • Prognostic models for renal cell carcinoma
          • International Metastatic RCC Database Consortium risk assessment system for stage IV renal cell carcinoma
          • UCLA Integrated Staging System for renal cell carcinoma
          • Classification of renal cell carcinoma
          • Staging of renal cell carcinoma
          • TNM staging system for renal cell carcinoma
          • Definitions of the TNM staging system for renal cell carcinoma
          • Key pathways and drug targets for renal cell carcinoma
      • Epidemiology
        • Key findings
          • Key updates
        • Epidemiology populations
          • Disease definition
          • Methods
          • Sources used for diagnosed incidence of renal cell carcinoma
          • Diagnosed incident cases of renal cell carcinoma: 2021-2031
          • Disease definition
          • Methods
          • Sources used for stage distribution of renal cell carcinoma
          • Diagnosed incident cases of renal cell carcinoma by stage distribution: 2021-2031
          • Disease definition
          • Methods
          • Sources used for recurrent incidence of renal cell carcinoma
          • Recurrent incident cases of renal cell carcinoma: 2021-2031
          • Renal cell carcinoma patient flow
          • Drug-Treatable Cases of Renal Cell Carcinoma: 2020-2030
          • Drug-treated cases of renal cell carcinoma: 2021-2031
      • Current treatment
        • Key findings
          • Treatment goals
            • Key endpoints used in clinical trials for renal cell carcinoma
          • Key current therapies
            • Overview
            • Mechanism of action of key current drug classes used for renal cell carcinoma
            • Current treatments used for renal cell carcinoma
            • Market events influencing the use of key current therapies in renal cell carcinoma
            • Key results from select clinical trials investigating Opdivo for the treatment of renal cell carcinoma
            • Ongoing clinical development of Opdivo
            • Key ongoing clinical trials of Opdivo in the treatment of renal cell carcinoma
            • Expert insight: Opdivo
            • Key results from select clinical trials investigating Opdivo and Yervoy combination therapy for the treatment of renal cell carcinoma
            • Ongoing clinical development of Opdivo and Yervoy combination therapy
            • Key ongoing clinical trials of Opdivo and Yervoy combination therapy in the treatment of renal cell carcinoma
            • Expert insight: Opdivo and Yervoy combination therapy
            • Key results from select clinical trials investigating Keytruda for the treatment of renal cell carcinoma
            • Ongoing clinical development of Keytruda
            • Key ongoing clinical trials of Keytruda in the treatment of renal cell carcinoma
            • Expert insight: Keytruda
            • Key results from select clinical trials investigating Bavencio for the treatment of renal cell carcinoma
            • Ongoing clinical development of Bavencio
            • Expert insight: Bavencio
            • Key results from select clinical trials investigating Sutent for the treatment of renal cell carcinoma
            • Expert insight: Sutent
            • Key results from select clinical trials investigating Votrient for the treatment of renal cell carcinoma
            • Expert insight: Votrient
            • Advantages and disadvantages of Nexavar
            • Expert insight: Nexavar
            • Key results from select clinical trials investigating Inlyta for the treatment of renal cell carcinoma
            • Expert insight: Inlyta
            • Expert insight: Avastin
            • Key results from select clinical trials investigating Cabometyx for the treatment of renal cell carcinoma
            • Ongoing clinical development of Cabometyx
            • Key ongoing clinical trials of Cabometyx in the treatment of renal cell carcinoma
            • Expert insight: Cabometyx
            • Key results from select clinical trials investigating Lenvima / Kisplyx for the treatment of renal cell carcinoma
            • Ongoing clinical development of Lenvima / Kisplyx
            • Expert insight: Lenvima / Kisplyx
            • Key results from select clinical trials investigating Fotivda for the treatment of renal cell carcinoma
            • Ongoing clinical development of Fotivda
            • Key ongoing clinical trials of Fotivda in the treatment of renal cell carcinoma
            • Expert insight: Fotivda
            • Advantages and disadvantages of Torisel
            • Expert insight: Torisel
            • Ongoing clinical development of Afinitor
            • Key ongoing clinical trials of Afinitor in the treatment of renal cell carcinoma
            • Expert insight: Afinitor
            • Key results from select clinical trials investigating Welireg for the treatment of renal cell carcinoma
            • Ongoing clinical development of Welireg
            • Key ongoing clinical trials of Welireg in the treatment of renal cell carcinoma
            • Expert insight: Welireg
          • Medical practice
            • Early-stage renal cell carcinoma: stages I-III
            • First-line advanced or metastatic renal cell carcinoma: stage IV
            • Second- and subsequent-line advanced or metastatic renal cell carcinoma
            • Patient characteristics influencing drug selection in renal cell carcinoma
            • Treatment decision tree for renal cell carcinoma: United States
            • Treatment decision tree for renal cell carcinoma: EU5
            • Treatment decision tree for renal cell carcinoma: Japan
        • Unmet need overview
          • Current and future attainment of unmet needs in renal cell carcinoma
          • Top unmet needs in renal cell carcinoma: current and future attainment
          • Expert insight: unmet need in renal cell carcinoma
        • Emerging therapies
          • Key findings
            • Key emerging therapies
              • Key therapies in development for renal cell carcinoma
              • Estimated market authorization dates of key emerging therapies for the treatment of renal cell carcinoma
              • Analysis of clinical development program for Tecentriq
              • Key ongoing clinical trials of Tecentriq in the treatment of renal cell carcinoma
              • Expert insight: Tecentriq
              • Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
              • Analysis of the clinical development program for Imfinzi
              • Key ongoing clinical trials of Imfinzi in the treatment of renal cell carcinoma
              • Expert insight: Imfinzi
              • Expectations for market authorization and sales opportunity of Imfinzi in renal cell carcinoma
              • Key results from select clinical trials investigating tremelimumab and Imfinzi combination therapy for the treatment of renal cell carcinoma
              • Analysis of clinical development program for tremelimumab and Imfinzi combination therapy
              • Key ongoing clinical trials of tremelimumab and Imfinzi combination therapy in the treatment of renal cell carcinoma
              • Expert insight: tremelimumab and Imfinzi combination therapy
              • Expectations for market authorization and sales opportunity of tremelimumab and Imfinzi combination therapy in renal cell carcinoma
              • Analysis of clinical development program for quavonlimab
              • Key ongoing clinical trials of quavonlimab in the treatment of renal cell carcinoma
              • Expert insight: quavonlimab
              • Expectations for market authorization and sales opportunity of quavonlimab in renal cell carcinoma
              • Key results from select clinical trials investigating Orpathys for the treatment of renal cell carcinoma
              • Analysis of clinical development program for Orpathys
              • Key ongoing clinical trials of Orpathys in the treatment of renal cell carcinoma
              • Expert insight: Orpathys
              • Expectations for market authorization and sales opportunity of Orpathys in renal cell carcinoma
              • Key results from select clinical trials investigating abexinostat for the treatment of renal cell carcinoma
              • Analysis of clinical development program for abexinostat
              • Key ongoing clinical trials of abexinostat in the treatment of renal cell carcinoma
              • Expert insight: abexinostat
              • Expectations for market authorization and sales opportunity of abexinostat in renal cell carcinoma
            • Early-phase pipeline analysis
              • Select compounds in early-phase development for renal cell carcinoma
          • Access and reimbursement overview
            • Region-specific reimbursement practices
              • Key market considerations in renal cell carcinoma: United States
              • General reimbursement environment: United States
              • Key market access considerations in renal cell carcinoma: EU5
              • General reimbursement environment: EU5
              • Key market access considerations in renal cell carcinoma: Japan
              • General reimbursement environment: Japan
          • Appendix
            • Abbreviations
            • Renal cell carcinoma bibliography

        Login to access report

        launch Related Market Assessment Reports